Should I buy or sell Avinger stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Avinger in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" AVGR shares. View AVGR analyst ratings or view top-rated stocks .

What is Avinger's stock price target for 2024?

1 analysts have issued 1-year target prices for Avinger's stock. Their AVGR share price targets range from $5.00 to $5.00. On average, they anticipate the company's share price to reach $5.00 in the next twelve months. This suggests a possible upside of 35.9% from the stock's current price. View analysts price targets for AVGR or view top-rated stocks among Wall Street analysts .

How have AVGR shares performed in 2024?

Avinger's stock was trading at $2.71 at the beginning of 2024. Since then, AVGR stock has increased by 35.8% and is now trading at $3.68. View the best growth stocks for 2024 here .

Are investors shorting Avinger?

Avinger saw a decrease in short interest in the month of March. As of March 31st, there was short interest totaling 50,300 shares, a decrease of 43.9% from the March 15th total of 89,600 shares. Based on an average trading volume of 52,900 shares, the short-interest ratio is presently 1.0 days. Approximately 3.6% of the company's stock are short sold. View Avinger's Short Interest .

When is Avinger's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our AVGR earnings forecast .

How were Avinger's earnings last quarter?

Avinger, Inc. (NASDAQ:AVGR) posted its quarterly earnings results on Wednesday, March, 20th. The medical device company reported ($3.93) earnings per share for the quarter, missing the consensus estimate of $0.64 by $4.57. The medical device company earned $1.91 million during the quarter, compared to analyst estimates of $2.52 million.

When did Avinger's stock split?

Shares of Avinger reverse split before market open on Wednesday, September 13th 2023. The 1-15 reverse split was announced on Wednesday, September 13th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, September 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Avinger own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Avinger investors own include Bionano Genomics (BNGO) , Novan (NOVN) , Titan Pharmaceuticals (TTNP) , Matinas BioPharma (MTNB) , Zosano Pharma (ZSAN) , Organigram (OGI) , Onconova Therapeutics (ONTX) , ADMA Biologics (ADMA) , Aeterna Zentaris (AEZS) and Actinium Pharmaceuticals (ATNM) .

When did Avinger IPO?

Avinger (AVGR) raised $60 million in an initial public offering (IPO) on Friday, January 30th 2015. The company issued 4,600,000 shares at $12.00-$14.00 per share. Canaccord Genuity and Cowen and Company served as the underwriters for the IPO and Oppenheimer, BTIG and Stephens were co-managers.

How do I buy shares of Avinger?

Shares of AVGR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:AVGR

Avinger (AVGR) Stock Price, News & Analysis

→ REVEALED: Elon Musk’s Secret A.I. Facility? (From InvestorPlace) (Ad)

Free AVGR Stock Alerts

$3.68

-0.60 (-14.02%)

(As of 04/15/2024 ET)

Compare

Today's Range: $3.66
▼
$4.25
50-Day Range: $2.61
▼
$5.34
52-Week Range: $2.50
▼
$18.00

Volume: 30,311 shs
Average Volume: 20,927 shs
Market Capitalization: $5.85 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $5.00

Get Avinger alerts:

Avinger MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 35.9% Upside
$5.00 Price Target
Short Interest: Healthy
3.64% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.78
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($2.08) to ($1.35) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.47 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
Avinger has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Avinger has only been the subject of 1 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
3.64% of the float of Avinger has been sold short.
Short Interest Ratio / Days to Cover
Avinger has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Avinger has recently decreased by 43.86%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Avinger does not currently pay a dividend.
Dividend Growth
Avinger does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for AVGR.

2.7

News and Social Media Coverage

News Sentiment
Avinger has a news sentiment score of 0.78. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Avinger this week, compared to 1 article on an average week.
Search Interest
Only 2 people have searched for AVGR on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Avinger to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Avinger insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.29% of the stock of Avinger is held by insiders.
Percentage Held by Institutions
Only 18.30% of the stock of Avinger is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Avinger are expected to grow in the coming year, from ($2.08) to ($1.35) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Avinger is -0.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Avinger is -0.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

Elon Musk’s ChatGPT Could Soon Mint New Millionaires

Elon Musk made $180 million on PayPal… $47 Billion on SpaceX…and $94.2 Billion on Tesla. He’s about to shock the world again with his version of ChatGPT.

And you could go along for the ride if you make this one simple move.

About Avinger Stock (NASDAQ:AVGR)

Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) in the United States and internationally. It develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. The company's lumivascular products comprise Lightbox imaging consoles, as well as the Ocelot family of catheters, including Ocelot and Tigereye, which are designed to allow physicians to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients. In addition, its chronic total occlusion (CTO)-crossing catheters, Wildcat and Kittycat 2, which employs a proprietary design that uses a rotational spinning technique allowing the physician to switch between passive and active modes when navigating across a CTO. Further, the company develops IMAGE-BTK for the treatment of PAD lesions below-the-knee. It markets and sells its products to interventional cardiologists, vascular surgeons, and interventional radiologists. The company was incorporated in 2007 and is headquartered in Redwood City, California.

AVGR Stock Price History

30 days | 90 days | 365 days | Advanced Chart

AVGR Stock News Headlines

April 16, 2024 | americanbankingnews.com

Avinger (NASDAQ:AVGR) Now Covered by Analysts at StockNews.com

April 14, 2024 | americanbankingnews.com

Financial Comparison: Sigyn Therapeutics (OTCMKTS:SIGY) and Avinger (NASDAQ:AVGR)

April 16, 2024 | InvestorPlace (Ad)

REVEALED: Elon Musk’s Secret A.I. Facility?

I recently shot this video outside what could be Elon Musk’s biggest secret. What’s happening inside these walls is so important that our government has declared it a matter of national security.

April 8, 2024 | americanbankingnews.com

StockNews.com Begins Coverage on Avinger (NASDAQ:AVGR)

April 3, 2024 | msn.com

Avinger files to sell 2.05M shares for holders

March 22, 2024 | seekingalpha.com

Avinger, Inc. (AVGR) Q4 2023 Earnings Call Transcript

March 21, 2024 | finance.yahoo.com

Avinger, Inc. (NASDAQ:AVGR) Q4 2023 Earnings Call Transcript

March 20, 2024 | investorplace.com

AVGR Stock Earnings: Avinger Misses Revenue for Q4 2023

April 16, 2024 | InvestorPlace (Ad)

REVEALED: Elon Musk’s Secret A.I. Facility?

I recently shot this video outside what could be Elon Musk’s biggest secret. What’s happening inside these walls is so important that our government has declared it a matter of national security.

March 12, 2024 | finance.yahoo.com

Avinger to Announce Full Year 2023 Results on March 20, 2024

March 11, 2024 | seekingalpha.com

Week In Review: EurekaBio Raises $40M To Support Lentiviral Vector Platform

March 7, 2024 | msn.com

Avinger enters partnership with Zylox-Tonbridge, to get $15 million of equity funding

March 7, 2024 | prnewswire.com

Zylox-Tonbridge and Avinger Forge Strategic Partnership to Expand Disruptive OCT Solutions for Peripheral Vascular Interventions

March 6, 2024 | finanznachrichten.de

Avinger, Inc.: Avinger Announces Strategic Partnership and up to $15 Million Equity Funding Agreement with Zylox-Tonbridge

March 6, 2024 | stockhouse.com

Important Notice to Avinger Investors and Aegis Capital Customers: Please Contact the Law Firm of KlaymanToskes

March 1, 2024 | yahoo.com

UT Tyler to host free health screenings in Avinger on Saturday

February 29, 2024 | edition.cnn.com

Avinger, Inc.

February 21, 2024 | benzinga.com

Why International Flavors & Fragrances Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

December 14, 2023 | health.usnews.com

Shanetia S. Avinger

December 1, 2023 | benzinga.com

Avinger Stock (NASDAQ:AVGR) Dividends: History, Yield and Dates

October 27, 2023 | finance.yahoo.com

Avinger, Inc. (NASDAQ:AVGR) Q3 2023 Earnings Call Transcript

October 26, 2023 | finanznachrichten.de

Avinger, Inc.: Avinger Reports Third Quarter 2023 Results

October 26, 2023 | finance.yahoo.com

Avinger Reports Third Quarter 2023 Results

October 26, 2023 | finance.yahoo.com

Avinger (AVGR) Reports Q3 Loss, Lags Revenue Estimates

October 25, 2023 | benzinga.com

Avinger Earnings Preview

October 19, 2023 | finance.yahoo.com

Avinger to Announce Third Quarter 2023 Results on October 26

September 27, 2023 | finanznachrichten.de

Avinger, Inc.: Avinger Raises $5.3 Million via At-The-Market Facility

See More Headlines

Receive AVGR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avinger and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/20/2024
Today: 4/16/2024
Next Earnings (Estimated): 5/08/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Surgical & medical instruments
Sub-Industry: N/A
Current Symbol: NASDAQ:AVGR
CUSIP: N/A
CIK: 1506928
Web: www.avinger.com
Phone: (650) 241-7900
Fax: 800-229-2696
Employees: 68
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $5.00
High Stock Price Target: $5.00
Low Stock Price Target: $5.00
Potential Upside/Downside: +35.9%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($26.3406)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-18,320,000.00
Net Margins: -239.41%
Pretax Margin: -239.41%
Return on Equity: N/A
Return on Assets: -106.16%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.63
Quick Ratio: 0.36

Sales & Book Value

Annual Sales: $7.65 million
Price / Sales: 0.76
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($4.53) per share
Price / Book: -0.81

Miscellaneous

Outstanding Shares: 1,590,000
Free Float: 1,518,000
Market Cap: $5.85 million
Optionable: Not Optionable
Beta: 1.26

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

Mr. Jeffrey M. Soinski (Age 62)
President, CEO & Director
Comp: $616.79k
Mr. Nabeel P. Subainati (Age 40)
VP of Finance, Principal Financial Officer & Accounting Officer
Comp: $347.58k
Mr. Himanshu N. Patel (Age 64)
Chief Technology Officer
Comp: $430.08k
Mr. Keith Schaefer
Chief Operating Officer
Mr. Corey Gibbs
Vice President of Sales
Dr. Jaafer Golzar FACC
M.D., Chief Medical Officer

Key Competitors

View All Competitors

AVGR Stock Analysis - Frequently Asked Questions

Should I buy or sell Avinger stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Avinger in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" AVGR shares.
View AVGR analyst ratings or view top-rated stocks.
What is Avinger's stock price target for 2024?: 1 analysts have issued 1-year target prices for Avinger's stock. Their AVGR share price targets range from $5.00 to $5.00. On average, they anticipate the company's share price to reach $5.00 in the next twelve months. This suggests a possible upside of 35.9% from the stock's current price.
View analysts price targets for AVGR or view top-rated stocks among Wall Street analysts.
How have AVGR shares performed in 2024?: Avinger's stock was trading at $2.71 at the beginning of 2024. Since then, AVGR stock has increased by 35.8% and is now trading at $3.68.
View the best growth stocks for 2024 here.
Are investors shorting Avinger?: Avinger saw a decrease in short interest in the month of March. As of March 31st, there was short interest totaling 50,300 shares, a decrease of 43.9% from the March 15th total of 89,600 shares. Based on an average trading volume of 52,900 shares, the short-interest ratio is presently 1.0 days. Approximately 3.6% of the company's stock are short sold.
View Avinger's Short Interest.
When is Avinger's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our AVGR earnings forecast.
How were Avinger's earnings last quarter?: Avinger, Inc. (NASDAQ:AVGR) posted its quarterly earnings results on Wednesday, March, 20th. The medical device company reported ($3.93) earnings per share for the quarter, missing the consensus estimate of $0.64 by $4.57. The medical device company earned $1.91 million during the quarter, compared to analyst estimates of $2.52 million.

When did Avinger's stock split?: Shares of Avinger reverse split before market open on Wednesday, September 13th 2023. The 1-15 reverse split was announced on Wednesday, September 13th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, September 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.
What other stocks do shareholders of Avinger own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Avinger investors own include Bionano Genomics (BNGO), Novan (NOVN), Titan Pharmaceuticals (TTNP), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Organigram (OGI), Onconova Therapeutics (ONTX), ADMA Biologics (ADMA), Aeterna Zentaris (AEZS) and Actinium Pharmaceuticals (ATNM).
When did Avinger IPO?: Avinger (AVGR) raised $60 million in an initial public offering (IPO) on Friday, January 30th 2015. The company issued 4,600,000 shares at $12.00-$14.00 per share. Canaccord Genuity and Cowen and Company served as the underwriters for the IPO and Oppenheimer, BTIG and Stephens were co-managers.
How do I buy shares of Avinger?: Shares of AVGR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AVGR) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial